News From Charter Oak Corporate Sponsors:
BMS 2026 Patient Advocacy Resources
Understanding CELMoDs (Cereblon E3 Ligase Modulatory Drugs)
BMS-activated treatment centers are expanding, providing the potential benefits of Breyanzi® to more patients
Exelixis 02/02/2026 Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Takeda Receives FDA 510(k) Clearance for HyHub™ and HyHub™ Duo Devices to Simplify HYQVIA® Administration 07/21/2025
Novocure 02/11/2026 U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
Regeneron Feb. 10, 2026 Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
Taiho 07/09/2025 Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content 06/30/2025
BMS U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels 06/26/2025
BMS 06/26/2025 U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
Astrazeneca 06/23/2025 Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Merck 06/13/2025 FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
BMS Nuvation Bio FDA approves taletrectinib for ROS1-positive non-small cell lung cancer 06/11/2025
Merck 05/31/2025 KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
Astellas Astellas Pharma US, Inc. is pleased to announce the U.S. Food and Drug Administration (FDA) approval of a 300 mg vial size (NDC: 0469-4425-30) for VYLOY (zolbetuximab-clzb) in addition to its current 100 mg vial size (NDC: 0469-3425-10). For more information, please visit VyloyHCP.com. 05/19/2025
Please click here for the full Prescribing Information.
For important state pricing disclosure information, click here
Important News and Information
Merck 04/27/2025 KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
BMS 04/11/2025 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMS 04/08/20025 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
Astrazeneca 03/31/2025 Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
Exelixis 03/26/2025 Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Exeixis 02/15/2025 Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
Pfizer U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma 02/12/2025 For more detailed information, please see the Full ADCETRIS Prescribing Information, including Boxed Warning.
Astrazeneca 01/27/2025 Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
Astrazeneca 01/17/2025 Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
Astrazeneca 01/17/2025 Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
01/07/2025 Pfizer Oncology is proud to announce the FDA approval of BRAFTOVI® (encorafenib) in a new indication as part of a combination regimen. The following information is available for State Society review:
Pfizer FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation 12/20/2024 BRAFTOVI Full Prescribing Information including Medication Guide
Astellas FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma 10/18/2024
BMS U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) 3/14/2024
Genentech FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer 10/15/2021
BMS Celgene COVID-19 Our Response and Path Forward - 05/13/2020
Exelixis announces first 100 patients enrolled in Phase 3 02/25/2020
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain 06/29/2020
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation 06/24/2020
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
06/17/2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
05/02/2020
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer
05/22/2020
Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations 04/27/2020
09/30/2019 AstraZeneca - Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years Press Release
08/16/2-19 Celgene -
U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis Press Release
09/29/2019 Merck - Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC) Press Release
10/01/2018 Takeda - Positive Results Press Release
09/25/2018 AstraZeneca - Overall Survival Press Release
09/24/2018 Astellas - Postive CHMP Opinion Press Release
08/06/2018 Teva - Updated Indication Press Release
06/28/2018 Array BioPharma - New Indication - BRAFTOVI™ (encorafenib) Press Release
03/26/2018 Seattle Genetics - FDA Breakthrough Therapy Designation Press Release
N02-11-2016 Merck - New Indication PressRelease.pdf
12-15-2015 - Genentech - ALECENSA® (alectinib) ALECENSAPracticeManagerDay1Letters_ATP.pdf
